Heat Biologics, Inc. (NASDAQ:HTBX) Files An 8-K Results of Operations and Financial Condition

Item 2.02 – Results of Operations and Financial Condition.

On May 11, 2017, Heat Biologics, Inc., a Delaware corporation
(the Registrant) issued a press release that included financial
information for the quarter ended March 31, 2017. A copy of the
press release is attached as Exhibit 99.1 to this Report on Form
8-K. The information contained in the press release is being
furnished to the Securities and Exchange Commission (the
Commission) and shall not be deemed incorporated by reference
into any of the Registrants registration statements or other
filings with the Commission.

Item 9.01 – Financial Statements and Exhibits.

About Heat Biologics, Inc. (NASDAQ:HTBX)

Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.

Heat Biologics, Inc. (NASDAQ:HTBX) Recent Trading Information

Heat Biologics, Inc. (NASDAQ:HTBX) closed its last trading session up +0.005 at 0.705 with 162,466 shares trading hands.